SMMTSummit Therapeutics Inc.
- BusinessWire
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit’s Expanding Network of Clinical Collaborations Underscore Confidence in Ivonescimab’s Potential Ivonescimab Global Clinical ...
- BusinessWire
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in BTC Ivonescimab Plus ...
- PR Newswire
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment BiologySEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit ...
- BusinessWire
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit’s AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology Summit Therapeutics Inc. (NASDAQ:SMMT) and Lunit Inc. ...
- BusinessWire
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Highlights Include Phase II Data Supporting Clinical Development Expansion for Ivonescimab Summit Therapeutics Inc. (NASDAQ:SMMT) today announced that ivonescimab data will be featured in numerous presentations at ...
- PR Newswire
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Becomes the 7th International Registrational Clinical Trial for IvonescimabClinical Trial Site Activations in the United States Expected to Begin Q4 2026HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: ...
- BusinessWire
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group ...
- BusinessWire
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
SMT112-216 Is a Randomized Multiregional Phase II Study Evaluating Ivonescimab Alone and in Combination with Cadonilimab or Ipilimumab in Previously Untreated Advanced ccRCC Study Is Being Conducted in Collaboration ...
- CNBC
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts. ...
- BusinessWire
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics Inc. (NASDAQ:SMMT) today announced the successful closing of AstraZeneca’s (NYSE:AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the ...
- CNBC
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer. ...
- BusinessWire
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Daiichi Sankyo (TSE: 4568) and AstraZeneca (NYSE:AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (NASDAQ:SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination ...
- BusinessWire
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer Summit Therapeutics Inc. ...
- Analyst Upgrades
Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20
Barclays analyst Etzer Darout maintains Summit Therapeutics with a Equal-Weight and raises the price target from $18 to $20. ...
- Analyst Upgrades
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics with a Buy and raises the price target from $40 to $43. ...
- BusinessWire
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price Summit Also Enters into ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics from Neutral to Neutral. ...
- BusinessWire
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III Ivonescimab Readout beyond NSCLC Demonstrates ...
- BusinessWire
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Sustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consistent across Geographic Regions; No New Safety Signals Observed Akeso-Sponsored HARMONi-2 OS Data Also Presented at WCLC 2026; Additional ...
- BusinessWire
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months PD-L1 High Expression Subgroup: Hazard Ratio = 0.58 Summit is ...
- Analyst Upgrades
Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25
Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics from Hold to Buy and raises the price target from $15 to $25. ...
- BusinessWire
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
Summit is Conducting HARMONi-7 in Patients with PD-L1 High-Expressing NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics from Neutral to Neutral. ...
- BusinessWire
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III Ivonescimab Readout beyond NSCLC Demonstrates ...
- Analyst Upgrades
Bernstein Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $11.9
Bernstein analyst Jeffrey Walch upgrades Summit Therapeutics from Underperform to Market Perform and raises the price target from $9.8 to $11.9. ...